Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Immunovant Inc (NASDAQ: IMVT) was $28.43 for the day, down -6.48% from the previous closing price of $30.40. In other words, the price has decreased by -$6.48 from its previous closing price. On the day, 1.81 million shares were traded. IMVT stock price reached its highest trading level at $30.345 during the session, while it also had its lowest trading level at $28.23.
Ratios:
Our analysis of IMVT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 22.14 and its Current Ratio is at 22.14. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on March 28, 2024, initiated with a Outperform rating and assigned the stock a target price of $50.
On March 13, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $50.
On February 20, 2024, JP Morgan started tracking the stock assigning a Overweight rating and target price of $51.JP Morgan initiated its Overweight rating on February 20, 2024, with a $51 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 09 ’24 when Salzmann Peter sold 4,807 shares for $31.18 per share. The transaction valued at 149,882 led to the insider holds 1,086,958 shares of the business.
Barnett Eva Renee sold 3,689 shares of IMVT for $115,023 on Apr 09 ’24. The Chief Financial Officer now owns 371,709 shares after completing the transaction at $31.18 per share. On Apr 09 ’24, another insider, Butchko Julia G., who serves as the Chief Development Officer of the company, sold 1,053 shares for $31.18 each. As a result, the insider received 32,833 and left with 461,742 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMVT now has a Market Capitalization of 4130679808 and an Enterprise Value of 3440048128.
Stock Price History:
The Beta on a monthly basis for IMVT is 0.72, which has changed by 0.86793697 over the last 52 weeks, in comparison to a change of 0.2160933 over the same period for the S&P500. Over the past 52 weeks, IMVT has reached a high of $45.58, while it has fallen to a 52-week low of $14.59. The 50-Day Moving Average of the stock is -15.12%, while the 200-Day Moving Average is calculated to be -10.54%.
Shares Statistics:
IMVT traded an average of 1.14M shares per day over the past three months and 1099270 shares per day over the past ten days. A total of 130.33M shares are outstanding, with a floating share count of 60.45M. Insiders hold about 58.40% of the company’s shares, while institutions hold 46.30% stake in the company. Shares short for IMVT as of 1711584000 were 9019835 with a Short Ratio of 7.89, compared to 1709164800 on 8682388. Therefore, it implies a Short% of Shares Outstanding of 9019835 and a Short% of Float of 12.9.
Earnings Estimates
The current market rating for Immunovant Inc (IMVT) reflects the collective analysis of 14 analysts closely monitoring its performance.On average, analysts expect EPS of -$0.43 for the current quarter, with a high estimate of -$0.35 and a low estimate of -$0.49, while EPS last year was -$0.46. The consensus estimate for the next quarter is -$0.45, with high estimates of -$0.39 and low estimates of -$0.53.
Analysts are recommending an EPS of between -$1.4 and -$1.93 for the fiscal current year, implying an average EPS of -$1.77. EPS for the following year is -$1.87, with 14 analysts recommending between -$0.83 and -$2.27.
